Guangdong Hybribio reports 2024 loss, sets aside impairment provisions

Guangdong Hybribio Biotech (SZSE:300639) reported a net loss of CNY645.75 million for 2024, alongside an announcement detailing significant asset impairment provisions. The company's management cited shifts in industry demands and adjustments in policies as key factors impacting revenue, further compounded by the reversal of deferred income tax assets and increased asset impairments. In response, the company plans to continue streamlining operations and control expenses.